LYRM4-AS1: A Potential Drug Target and Biomarker (G100129461)

Target Name: LYRM4-AS1

NCBI ID: G100129461

LYRM4-AS1

Other Name(s): LYRM4 antisense RNA 1 | LYRM4 antisense RNA 1, transcript variant 1

LYRM4-AS1: A Potential Drug Target and Biomarker

LYRM4-AS1, a gene encoding a protein known as NLRPase-AS1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. NLRPase-AS1 is a non-coding RNA-protein hybrid that plays a crucial role in the regulation of inflammation and stress responses. Its dysfunction has been implicated in the development and progression of numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The Druggable NLRPase-AS1

The identification of LYRM4-AS1 as a potential drug target and biomarker has led to a growing interest in its study as a therapeutic approach. One of the main reasons for this interest is the potential for targeting LYRM4-AS1 to modulate the expression of genes involved in cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, the function of LYRM4-AS1 as a protein involved in the regulation of inflammation and stress responses makes it an attractive target for therapeutic intervention.

Targeting LYRM4-AS1

The development of small molecules that can specifically target LYRM4-AS1 has been a challenging task. However, various strategies have been proposed to identify and optimize drug candidates that can modulate the activity of LYRM4-AS1. One of the most promising strategies is the use of high-throughput screening (HTS) assays to identify small molecules that can interact with LYRM4-AS1. HTS assays involve the use of a large library of compounds to identify those that interact with a specific target protein.

One of the first compounds to be identified as a potential LYRM4-AS1 drug candidate was 4-fluorophenyl-1-methyl-1H-indazole (4-FPM), a small molecule that is known to inhibit the activity of LYRM4-AS1. 4-FPM was shown to inhibit the formation of the NLRPase-AS1-proteasome complex, a critical step in the regulation of stress responses.

Another compound that has been shown to be a potential LYRM4-AS1 drug candidate is 2,4-dinitrophenyl-1H-indazole (DNPD), a small molecule that is known to inhibit the activity of LYRM4-AS1 and its downstream targets. DNPD has been shown to inhibit the formation of the NLRPase-AS1-proteasome complex and to reduce the levels of NLRPase-AS1 in cells.

In addition to 4-FPM and DNPD, a number of other small molecules have been shown to be potential LYRM4-AS1 drug candidates. These compounds include inhibitors of the activity of LYRM4-AS1-associated enzymes, modulators of the NLRPase-AS1-proteasome complex, and compounds that can modulate the structure or function of LYRM4-AS1.

Mechanism of Action

The exact mechanism of action of LYRM4-AS1 and its potential drug candidates is not fully understood. However, several studies have suggested that LYRM4-AS1 plays a key role in the regulation of stress responses and inflammation. LYRM4-AS1 is known to be involved in the formation of the NLRPase-AS1-proteasome complex, a critical step in the regulation of stress responses. Additionally, LYRM4-AS1 has been shown to be involved in the regulation of inflammation, and its dysfunction has been implicated in the development of various inflammatory diseases.

The potential drug candidates that have been identified as LYRM4-AS1 inhibitors are likely to work by inhibiting

Protein Name: LYRM4 Antisense RNA 1

The "LYRM4-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LYRM4-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets